Torrent Pharma Recalls Over 27,000 Bottles Of Blood Pressure Drug In US

Torrent Pharma is recalling more than 27,000 bottles of its generic drug, used in lowering high blood pressure, in the US market.

As per the latest enforcement report by the US Food and Drug Administration (USFDA), the Ahmedabad-based company is recalling 27,312 bottles of the Telmisartan and Hydrochlorothiazide tablets.

The affected lot has been produced in India and later the company has supplied to its US-based subsidiary for distribution in the US, the world's largest market for generic drugs.

According to the US health regulator, the drug maker is recalling the affected lot due to it being "Superpotent; Hydrochlorothiazide."

New Jersey-based Torrent Pharma Inc, a unit of the company, has initiated the Class III nationwide (US) recall of the 40 mg/12.5 mg, 30 count bottles on December 1, this year.

Telmisartan Hydrochlorothiazide comprises two medicines, both of which help to control high blood pressure.

It is generally used when one medicine alone is not controlling the blood pressure effectively.

Lowering blood pressure helps to reduce your risk of having a heart attack or a stroke.

As per USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences."

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor